Notably, a novel KRASR68S1 alteration (Figure 2) was identified in a 41-year-old female (1.4%) with rectal cancer and synchronous metastases to the liver and retroperitoneal and supraclavicular lymph nodes who experienced PD at 2 months on anti-EGFR therapy with second-line irinotecan + cetuximab. The gene discussed is EGFR; the disease is rectal cancer.